The role of iron in the pathophysiology and treatment of chronic hepatitis C

Canadian Journal of Gastroenterology

Volumn 23, Issue 12, 2009, Pages 822-828

  Price, Leslie ^a   Kowdley, Kris V ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Hemochromatosis; Hepatitis C; Iron overload

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; HFE PROTEIN; INTERFERON; IRON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

CANCER RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; GENE MUTATION; HEMOCHROMATOSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; IRON DEPLETION; IRON METABOLISM; IRON OVERLOAD; IRON RESTRICTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER HISTOLOGY; LIVER LEVEL; NONHUMAN; PATHOPHYSIOLOGY; PHLEBOTOMY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; TREATMENT RESPONSE;

EID: 73349085875     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/290383     Document Type: Review

References (61)

1. Disease burden from hepatitis C in the US. (Version current at June 24, 2008).
2. Hepatitis C. (version current at October 1, 2000).
3. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
4. Thursz M. Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection. Gut 2007;56:613-4.
5. Fujita N, Sugimoto R, Ma N, et al. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. J Viral Hepatol 2008;15:498-507.
6. Martinelli AL, Ramalho LN, Zucoloto S. Hepatic stellate cells in hepatitis C patients: Relationship with liver iron deposits and severity of liver disease. J Gastroenterol Hepatol 2004;19:91-8.
7. Nishina S, Hino K, Korenaga M, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008;134:226-38.
8. Trinder D, Ayonrinde OT, Olynyk JK. HCV, iron, and oxidative stress: The new choreography of hepcidin. Gastroenterology 2008;134:348-51.
9. Fujita N, Sugimoto R, Takeo M, et al. Hepcidin expression in the liver: Relatively low level in patients with chronic hepatitis C. Mol Med 2007;13:97-104.
10. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997;25:759-68.
11. Fujita N, Sugimotot R, Urawa N, et al. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ ribavirin combination therapy in chronic hepatitis C. J Gastroenterol Hepatol 2007;22:1886-93.
12. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992;102:2108-13.
13. Hezode C, Cazeneuve C, Coue O, et al. Liver iron accumulation in patients with chronic active hepatitis C: Prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol 1999;31:979-84.
14. Olynyk JK, Reddy KR, Di Bisceglie AM, et al. Hepatic iron concentration as a predictor of response to interferon-alfa therapy in chronic hepatitis C. Gastroenterology 1995;108:1104-9.
15. Bonkovsky HL, Naishadham D, Lambreacht RW, et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006;131:1440-51.
16. Tung BY, Emond MJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: Relationship with HFE mutations. Gastroenterology 2003;124:318-26.
17. Smith BC, Grove J, Guzail MA, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27:1695-9.
18. Piperno A, Vergani A, Malosio D, et al. Hepatic iron overload in patients with chronic viral hepatitis: Role of HFE gene mutations. Hepatology 1998;28:1105-9.
19. Bonkovsky HL, Troy N, McNeal K, et al. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol 2002;37:848-54.
20. Kazemi-Shirazi L, Datz C, Maier-Dobersberger T, et al. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999;116:127-34.
21. Erhardt A, Maschner-Olberg A, Mellenthin C, et al. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol 2003;38:335-42.
22. Gehrke S, Stremmel W, Mathes I, Riedel H, Bents K, Kallinowski B. Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: Impact on iron status, liver injury, and HCV genotype. J Mol Med 2003;81:780-7.
23. Geier A, Reugels M, Weiskirchen R, et al. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C. Liv Int 2004;24:285-94.
24. Thorburn D, Curry G, Spooner R, et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002;50:248-52.
25. Lal P, Fernandes H, Koneru B, Albanese E, Hameed M. C282Y mutation and hepatic iron status in hepatitis C and cryptogenic cirrhosis. Arch Pathol Lab Med 2000;124:1632-5.
26. Pirisi M, Scott CA, Avellini C, et al. Iron deposition and progression of disease in chronic hepatitis C. Am J Clin Pathol 2000;113:546-54.
27. Negro F, Samii K, Rubbia-Brandt L, et al. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. J Med Virol 2000;60:21-7.
28. Hohler T, Leininger S, Kohler HH, Schirmacher P, Galle PR. Heterozygosity for the hemochromatosis gene in liver diseases -prevalence and effects on liver histology. Liver 2000;20:482-6.
29. Cauza E, Peck-Radosavljevic M, Ulrich-Pur H, et al. Mutations of the HFE gene in patients with hepatocellular carcinoma. Am J Gastroenterol 2003;98:442-7.
30. Hellerbrand C, Poppl A, Hartmann A, Scholmerich J, Lock G. HFE C282Y heterozygosity in hepatocellular carcinoma: Evidence for an increased prevalence. Clin Gastroenterol Hepatol 2003;1:279-84.
31. Lauret E, Rodriguez M, Gonzalez S, et al. HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. Am J Gastroenterol 2002;97:1016-21.
32. Boige V, Castera L, de Roux N, et al. Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosis. Gut 2003;52:1178-81.
33. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004;127:S79-S86.
34. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 1994;20:410-15.
35. Ikura Y, Morimoto H, Johmura H, Fukui M, Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol 1996;91:1367-73.
36. Fontana RJ, Israel J, LeClair P, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial. Hepatology 2000;31:730-6.
37. Fargion S, Fracanzani AL, Rossini A, et al. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: Results of an Italian multicenter randomized study. Am J Gastroenterol 2002;97:1204-10.
38. Fong TL, Han SH, Tsai NC, et al. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alphainterferon in patients with chronic hepatitis C. J Hepatol 1998;28:369-74.
39. Carlo C, Daniela P, Giancarlo C. Iron depletion and response to interferon in chronic hepatitis C. Hepatol Gastroenterol 2003;50:1467-71.
40. Piperno A, Sampietro M, D'Alba R, et al. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996;16:248-54.
41. Desai TK, Jamil LH, Balasubramaniam M, Koff R, Bonkovsky HL. Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: A meta-analysis of six prospective randomized controlled trials. Dig Dis Sci 2008;53:815-22.
42. Di Bisceglie AM, Bonkovsky HL, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial. Hepatology 2000;32:135-8.
43. Guyader D, Boucher E, Andre P, et al. A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon. Am J Gastroenterol 1999;94:1696-8.
44. Alexander J, Tung BY, Croghan A, Kowdley KV. Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: Results of a pilot study. Liver Int 2007;27:268-73.
45. Tsai N, Zuckerman E, Han SH, Goad K, Redeker AG, Fong TL. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterol 1997;92:1831-4.
46. Van Thiel DH, Friedlander L, Molloy PJ, et al. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. Hepatogastroenterology 1996;43:1557-61.
47. Coelho-Borges S, Cheinquer H, Cheinquer N, Krug L, Ashton-Prollo P. HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload. AJG 2002;97:1570-2.
48. Yano M, Hayashi H, Yoshioka K, et al. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: A multicenter, prospective, randomized, controlled trial in Japan. J Gastroenterol 2004;39:570-4.
49. Yano M, Hayashi H, Wakusawa S, et al. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol 2002;97:133-7.
50. Kawamura Y, Akuta N, Sezaki H, et al. Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. J Gastroenterol 2005;40:901-6.
51. Hofer H, Osterreicher C, Jessner W, et al. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J Hepatol 2004;40:1018-22.
52. Rulyak SJ, Eng SC, Patel K, McHutchinson JG, Gordon SC, Kowdley K. Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. Am J Gastroenterol 2005;100:332-7.
53. Pianko S, McHutchison JG, Gordon SC, et al. Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. J Interferon Cytokine Res 2002;22:483-9.
54. Takakazu F, Keisuke H, Michiari O, et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006;130:2087-98.
55. Chapoutot C, Esslimani M, Joomaye Z, et al. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. Gut 2000;46:711-4.
56. Ko C, Siddaiah N, Berger J, et al. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: Results from the National Hemochromatosis Transplant Registry. Liv Int 2007;27:1394-1401.
57. Kato J, Miyanishi K, Kobune M, et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007;42:830-6.
58. Kato J, Kobune M, Nakamura T, et al. Normalization of elevated hepatic 8-hydroxy-2-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 2001;61:8697-702.
59. Tanaka H, Fujita N, Sugimoto R, et al. Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. BJC 2008;98:580-6.
60. Tandon N, Thaker V, Kumkar R, Guptan C, Sarin SK. Beneficial influence of an indigenous low-iron diet on serum indicators of iron status in patients with chronic liver disease. British J Nutr 2000;83:235-9.
61. Sumida Y, Kanemasa K, Fukumoto K, Yoshida N, Sakai K. Effects of dietary iron reduction versus phlebotomy in patients with chronic hepatitis C: Results from a randomized, controlled trial on 40 Japanese patients. Intern Med 2007;46:637-42.